Filtered By:
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 20131 results found since Jan 2013.
Dosimetric impact of MLC positional errors on dose distribution in IMRT
This study investigates dose sensitivity variations and complexity metrics of MLC positional error in volumetric modulated arc therapy and determines the acceptable ranges of MLC positional accuracy in several clinical situations. Treatment plans were generated for four treatment sites (prostate cancer, lung cancer, spinal, and brain metastases) using different treatment planning systems (TPSs) and fraction sizes. Each treatment plan introduced 0.25-2.0 mm systematic or random MLC leaf bank errors. The generalized equivalent uniform dose (gEUD) sensitivity and complexity metrics (MU/Gy and plan irregularity) were calculate...
Source: Clinical Prostate Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Hiromi Enomoto Yukio Fujita Saki Matsumoto Yujiro Nakajima Miyuki Nagai Ayako Tonari Takeshi Ebara Source Type: research
Histone mutations in cancer
Biochem Soc Trans. 2023 Sep 18:BST20210567. doi: 10.1042/BST20210567. Online ahead of print.ABSTRACTGenes encoding histone proteins are recurrently mutated in tumor samples, and these mutations may impact nucleosome stability, histone post-translational modification, or chromatin dynamics. The prevalence of histone mutations across diverse cancer types suggest that normal chromatin structure is a barrier to tumorigenesis. Oncohistone mutations disrupt chromatin structure and gene regulatory mechanisms, resulting in aberrant gene expression and the development of cancer phenotypes. Examples of oncohistones include the histo...
Source: Biochemical Society Transactions - September 18, 2023 Category: Biochemistry Authors: Kimberly N Espinoza Pereira Jixiu Shan Jonathan D Licht Richard L Bennett Source Type: research
Caregivers matter: Neurological vulnerability for pediatric brain tumor survivors
CONCLUSIONS: Heightened associations between parenting and QOL in the context of neurotoxic treatments underscore the need to better support PBTS. Findings are consistent with research suggesting that family factors may be particularly important for children with other neurological insults. Limitations include cross-sectional design and a small/heterogeneous clinical sample with low ethnic/racial diversity. Prospective studies are needed to refine evidence-based screening and develop psychosocial intervention strategies to optimize QOL for PBTS and their families.PMID:37720398 | PMC:PMC10502790 | DOI:10.1093/nop/npad010
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Emily L Moscato Allison P Fisher Natasha Pillay-Smiley Ralph Salloum Shari L Wade Source Type: research
Histone mutations in cancer
Biochem Soc Trans. 2023 Sep 18:BST20210567. doi: 10.1042/BST20210567. Online ahead of print.ABSTRACTGenes encoding histone proteins are recurrently mutated in tumor samples, and these mutations may impact nucleosome stability, histone post-translational modification, or chromatin dynamics. The prevalence of histone mutations across diverse cancer types suggest that normal chromatin structure is a barrier to tumorigenesis. Oncohistone mutations disrupt chromatin structure and gene regulatory mechanisms, resulting in aberrant gene expression and the development of cancer phenotypes. Examples of oncohistones include the histo...
Source: Biochemical Society Transactions - September 18, 2023 Category: Biochemistry Authors: Kimberly N Espinoza Pereira Jixiu Shan Jonathan D Licht Richard L Bennett Source Type: research
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.PMID:37718781 | DOI:10.3233/CBM-230159
Source: Cancer Biomarkers : Section A of Disease Markers - September 18, 2023 Category: Cancer & Oncology Authors: Ismail Beyp ınar Y ıldız Sözel Arif Hakan Önder Source Type: research
Dosimetric impact of MLC positional errors on dose distribution in IMRT
This study investigates dose sensitivity variations and complexity metrics of MLC positional error in volumetric modulated arc therapy and determines the acceptable ranges of MLC positional accuracy in several clinical situations. Treatment plans were generated for four treatment sites (prostate cancer, lung cancer, spinal, and brain metastases) using different treatment planning systems (TPSs) and fraction sizes. Each treatment plan introduced 0.25-2.0 mm systematic or random MLC leaf bank errors. The generalized equivalent uniform dose (gEUD) sensitivity and complexity metrics (MU/Gy and plan irregularity) were calculate...
Source: Clinical Lung Cancer - September 18, 2023 Category: Cancer & Oncology Authors: Hiromi Enomoto Yukio Fujita Saki Matsumoto Yujiro Nakajima Miyuki Nagai Ayako Tonari Takeshi Ebara Source Type: research
Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence
Mol Cancer Ther. 2023 Sep 19. doi: 10.1158/1535-7163.MCT-23-0026. Online ahead of print.ABSTRACTTherapeutic resistance remains a major obstacle to successful clinical management of Diffuse Intrinsic Pontine Glioma (DIPG), a high-grade pediatric tumor of the brain stem. In nearly all patients, available therapies fail to prevent progression. Innovative combinatorial therapies that penetrate the blood-brain barrier and lead to long-term control of tumor growth are desperately needed. We identified mechanisms of resistance to radiotherapy, the standard of care for DIPG. Based on these findings, we rationally designed a brain-...
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Monika Sharma Ivana Barravecchia Robert Teis Jeanette Cruz Rachel Mumby Elizabeth K Ziemke Carlos E Espinoza Varunkumar Krishnamoorthy Brian Magnuson Mats Ljungman Carl Koschmann Joya Chandra Christopher E Whitehead Judith S Sebolt-Leopold Stefanie Galban Source Type: research
Histone mutations in cancer
Biochem Soc Trans. 2023 Sep 18:BST20210567. doi: 10.1042/BST20210567. Online ahead of print.ABSTRACTGenes encoding histone proteins are recurrently mutated in tumor samples, and these mutations may impact nucleosome stability, histone post-translational modification, or chromatin dynamics. The prevalence of histone mutations across diverse cancer types suggest that normal chromatin structure is a barrier to tumorigenesis. Oncohistone mutations disrupt chromatin structure and gene regulatory mechanisms, resulting in aberrant gene expression and the development of cancer phenotypes. Examples of oncohistones include the histo...
Source: Biochemical Society Transactions - September 18, 2023 Category: Biochemistry Authors: Kimberly N Espinoza Pereira Jixiu Shan Jonathan D Licht Richard L Bennett Source Type: research
Nanoarchitectured conjugates targeting angiogenesis: investigating heparin-taurocholate acid conjugates (LHT7) as an advanced anti-angiogenic therapy for brain tumor treatment
CONCLUSIONS: The conjugation of heparin and taurocholic acid to create LHT7 offers several advantages over conventional therapeutic approaches for glioblastoma. LHT7 demonstrated anti-angiogenic properties, as evidenced by the reduction in cell viability and inhibition of endothelial cell sprouting. Moreover, LHT7 modulated the phosphorylation of angiogenesis-related proteins. These findings suggest that LHT7 holds promise as a medication for glioblastoma treatment, offering potential implications for improving patient outcomes.PMID:37723574 | PMC:PMC10506202 | DOI:10.1186/s40824-023-00420-8
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Hyung Shik Kim Jae Hak Seol Hae Hyun Hwang Dong Yun Lee Source Type: research
HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer
Cancer Res Commun. 2023 Sep 11. doi: 10.1158/2767-9764.CRC-23-0302. Online ahead of print.ABSTRACTThe oncogenic receptor HER2 is overexpressed in many cancers, including up to 20% of breast cancers. Despite the availability of HER2-targeted treatments, patients' disease often progresses during therapy, underscoring the need for novel treatment strategies. The addition of tucatinib, a reversible, highly selective HER2 tyrosine kinase inhibitor (TKI), to treatment with trastuzumab and capecitabine significantly improved survival outcomes of patients with HER2-positive metastatic breast cancer, including those with active bra...
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Devra Olson Janelle Taylor Kelsi Willis Kelly Hensley Sean Allred Margo Zaval Lauren Farr Robert Thurman Nishi Jain Renee Hein Michelle Ulrich Scott Peterson Anita Kulukian Source Type: research
Dosimetric impact of MLC positional errors on dose distribution in IMRT
This study investigates dose sensitivity variations and complexity metrics of MLC positional error in volumetric modulated arc therapy and determines the acceptable ranges of MLC positional accuracy in several clinical situations. Treatment plans were generated for four treatment sites (prostate cancer, lung cancer, spinal, and brain metastases) using different treatment planning systems (TPSs) and fraction sizes. Each treatment plan introduced 0.25-2.0 mm systematic or random MLC leaf bank errors. The generalized equivalent uniform dose (gEUD) sensitivity and complexity metrics (MU/Gy and plan irregularity) were calculate...
Source: Health Physics - September 18, 2023 Category: Physics Authors: Hiromi Enomoto Yukio Fujita Saki Matsumoto Yujiro Nakajima Miyuki Nagai Ayako Tonari Takeshi Ebara Source Type: research
Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.PMID:37718781 | DOI:10.3233/CBM-230159
Source: Cancer Biomarkers : Section A of Disease Markers - September 18, 2023 Category: Cancer & Oncology Authors: Ismail Beyp ınar Y ıldız Sözel Arif Hakan Önder Source Type: research
Dosimetric impact of MLC positional errors on dose distribution in IMRT
This study investigates dose sensitivity variations and complexity metrics of MLC positional error in volumetric modulated arc therapy and determines the acceptable ranges of MLC positional accuracy in several clinical situations. Treatment plans were generated for four treatment sites (prostate cancer, lung cancer, spinal, and brain metastases) using different treatment planning systems (TPSs) and fraction sizes. Each treatment plan introduced 0.25-2.0 mm systematic or random MLC leaf bank errors. The generalized equivalent uniform dose (gEUD) sensitivity and complexity metrics (MU/Gy and plan irregularity) were calculate...
Source: Journal of Applied Clinical Medical Physics - September 18, 2023 Category: Physics Authors: Hiromi Enomoto Yukio Fujita Saki Matsumoto Yujiro Nakajima Miyuki Nagai Ayako Tonari Takeshi Ebara Source Type: research
